Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation

Oncogene

Volumn 27, Issue 22, 2008, Pages 3156-3164

  Jiao, W ^a   Lin, H M ^a,c   Datta, J ^a   Braunschweig, T ^b   Chung, J Y ^b   Hewitt, S M ^b   Rane, S G ^a,c  

^a Laboratory of Cell Regulation and Carcinogenesis   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cancer; CDK; Differentiation; Export; Localization; RB

Indexed keywords

CYCLIN DEPENDENT KINASE; EXPORTIN 1; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CELL DIFFERENTIATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM TUMOR; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOPLASM; EMBRYO; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LYMPHOMA; MALE; MELANOMA; MOUSE; NEOPLASM; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; TUMOR PROMOTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL DIFFERENTIATION; CELL NUCLEUS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASES; DISEASE PROGRESSION; HCT116 CELLS; HT29 CELLS; HUMANS; KARYOPHERINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PHOSPHORYLATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETINOBLASTOMA PROTEIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 43749117336     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210970     Document Type: Article

References (52)

1. Alkarain A, Jordan R, Slingerland J. (2004). p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 9: 67-80.
2. Blain SW, Massague J. (2002). Breast cancer banishes p27 from nucleus. Nat Med 8: 1076-1078.
3. Boyd SD, Tsai KY, Jacks T. (2000). An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol 2: 563-568.
4. Braunschweig T, Chung JY, Hewitt SM. (2005). Tissue microarrays: bridging the gap between research and the clinic. Expert Rev Proteomics 2: 325-336.
5. Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE et al. (2004). Flavopiridol enhances human tumor cell radio-sensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther 3: 409-416.
6. Chestukhin A, Litovchick L, Rudich K, DeCaprio JA. (2002). Nucleocytoplasmic shuttling of p130/RBL2: novel regulatory mechanism. Mol Cell Biol 22: 453-468.
7. Classon M, Harlow E. (2002). The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2: 910-917.
8. Durfee T, Mancini MA, Jones D, Elledge SJ, Lee WH. (1994). The amino-terminal region of the retinoblastoma gene product binds a novel nuclear matrix protein that co-localizes to centers for RNA processing. J Cell Biol 127: 609-622.
9. Geyer RK, Yu ZK, Maki CG. (2000). The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2: 569-573.
10. Goodrich DW. (2006). The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene 25: 5233-5243.
11. Haluska FG, Hodi FS. (1998). Molecular genetics of familial cutaneous melanoma. J Clin Oncol 16: 670-682.
12. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
13. Henderson BR. (2000). Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol 2: 653-660.
14. Inman GJ, Nicolas FJ, Hill CS. (2002). Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell 10: 283-294.
15. Jiao W, Datta J, Lin HM, Dundr M, Rane SG. (2006). Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export. J Biol Chem 281: 38098-38108.
16. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. (1979). Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23.
17. Kastan MB, Zambetti GP. (2003). Parc-ing p53 in the cytoplasm. Cell 112: 1-2.
18. Kau TR, Way JC, Silver PA. (2004). Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4: 106-117.
19. Khidr L, Chen PL. (2006). RB, the conductor that orchestrates life, death and differentiation. Oncogene 25: 5210-5219.
20. Knudsen ES, Wang JY. (1997). Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 17: 5771-5783.
21. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K et al. (2002). PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153-1160.
22. Liggett Jr WH, Sidransky D. (1998). Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197-1206.
23. Lu S, Tsai SY, Tsai MJ. (1997). Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 57: 4511-4516.
24. Malumbres M, Barbacid M. (2001). To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231.
25. Mittnacht S, Lees JA, Desai D, Harlow E, Morgan DO, Weinberg RA. (1994). Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J 13: 118-127.
26. Mittnacht S, Weinberg RA. (1991). G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell 65: 381-393.
27. Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E et al. (2001). E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 15: 267-285.
28. Nork TM, Millecchia LL, Poulsen G. (1994). Immunolocalization of the retinoblastoma protein in the human eye and in retinoblastoma. Invest Ophthalmol Vis Sci 35: 2682-2692.
29. Ortega S, Malumbres M, Barbacid M. (2002). Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73-87.
30. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L et al. (1989). Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092.
31. Rane SG, Cosenza SC, Mettus RV, Reddy EP. (2002). Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol 22: 644-656.
32. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP et al. (1999). Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 22: 44-52.
33. Rosin-Arbesfeld R, Townsley F, Bienz M. (2000). The APC tumour suppressor has a nuclear export function. Nature 406: 1009-1012.
34. Schwartz GK, Shah MA. (2005). Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23: 9408-9421.
35. Sedlacek HH. (2001). Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 38: 139-170.
36. Shapiro GI. (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770-1783.
37. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J et al. (2002). PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8: 1145-1152.
38. Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M et al. (2001a). Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J 20: 6637-6647.
39. Sotillo R, Garcia JF, Ortega S, Martin J, Dubus P, Barbacid M et al. (2001b). Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci USA 98: 13312-13317.
40. Stade K, Ford CS, Guthrie C, Weis K. (1997). Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 90: 1041-1050.
41. Stevens C, La Thangue NB. (2003). E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 412: 157-169.
42. Stokke T, Erikstein BK, Smedshammer L, Boye E, Steen HB. (1993). The retinoblastoma gene product is bound in the nucleus in early G1 phase. Exp Cell Res 204: 147-155.
43. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC. (2002). A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99: 5515-5520.
44. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D et al. (2002). Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8: 1136-1144.
45. Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP et al. (1992). Neural computing in cancer drug development: predicting mechanism of action. Science 258: 447-451.
46. Weis K. (2003). Regulating access to the genome: nucleocytoplasmic transport throughout the cell cycle. Cell 112: 441-451.
47. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E et al. (1995). A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284.
48. Xu L, Massague J. (2004). Nucleocytoplasmic shuttling of signal transducers. Nat Rev Mol Cell Biol 5: 209-219.
49. Yen A, Coder D, Varvayanis S. (1997). Concentration of RB protein in nucleus vs cytoplasm is stable as phosphorylation of RB changes during the cell cycle and differentiation. Eur J Cell Biol 72: 159-165.
50. Zacksenhaus E, Bremner R, Phillips RA, Gallie BL. (1993). A bipartite nuclear localization signal in the retinoblastoma gene product and its importance for biological activity. Mol Cell Biol 13: 4588-4599.
51. Ziegler EC, Ghosh S. (2005). Regulating inducible transcription through controlled localization. Sci STKE 2005: re6.
52. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ et al. (1996). Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12: 97-99.